Two phase III trials published in The Lancet and JAMA offer three essential insights for clinicians managing type 2 diabetes. First, orforglipron delivers clinically meaningful HbA1c reductions when combined with metformin or insulin glargine, with reductions reaching 1.5% in combination therapy—substantial improvements for glycaemic control. Second, the once-weekly dosing regimen addresses a persistent challenge in diabetes care: treatment adherence. Less frequent dosing schedules correlate with improved patient compliance and sustained therapeutic benefit. Third, the drug’s tolerability profile extends GLP-1 receptor agonist options to diverse patient populations, enabling more personalised therapeutic approaches. These findings, presented at the American Diabetes Association annual meeting in June 2026, reinforce the role of GLP-1 agonists as cornerstone agents in type 2 diabetes combination therapy.
Was this article helpful?
